anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Medical diagnostic images are sent and received, when received the digital image data is modified by deleting private patient information in the digital image data. Contact information for a medical professional associated with the received medical diagnostic image is then selected and the digital image data is modified by embedding the selected contact information into the modified digital image data for the medical diagnostic image. The modified digital image data and the embedded contact information are sent over a network so the image can be shared by the client with others. Personalized contact messages may also be embedded in non-medical images for sharing with others. Embedded contact messages may be embedded as a watermark, or using layering techniques or substitution techniques. The contact messages may include hyperlinks, coupons, quick response codes, electronic business card or contact information and are visible or accessible to a recipient.
Placebo Comparator: Placebo The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 containing sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml. The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks. The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
After signing the informed consent, inpatients (Senior trauma center/heart surgery) will do the dietary assessment with the eNutrition optimizer with supervision of a trained study physician to assess user feasibility in the inpatient setting. In addition they will have a follow-up phone call at month 3 to 6 to assess the subjective effectiveness of the eNO.
Subjects assigned to this group will wear the splints but instructed to wear the device in a position that produces no stretch. Splint devices will be worn at the assigned angle 5 days/week, 30 minutes/day, for 4 weeks. ABI, muscle oxygenation, and walking distance will be assessed pre/post stretching. Other health surveys will be administered.
The invention relates to orthodontic adhesives formulated with trimethylolpropane trimethacrylate (TMPTMA) that do not contain BisGMA. These adhesives removed the mutagenic and teratogenic risk caused by the release of bisphenol A and presented an improved performance compared to three commercial adhesives prepared with BisGMA (Adhesive A, Adhesive C and Adhesive B). The invention provides a single-step adhesive and a fluid paste. The adhesives of the invention were compared with two commercial controls and were physically characterized considering: hardness time, adhesion strength, elastic module, sorption and solubility at different pH (6. 8 and 7.7); the obtained characteristics avoid early detachments, white lesions under the appliances and microfiltration; the fluidity was assessed as well as the thickness of the film and were compared with the values obtained from the three commercial adhesives. The storage stability was assessed as well as the thermogravimetric analysis. The ad hesives prepared with TMPTMA are photopolymerizable so that provide enough time to the operator for placing the appliances in a suitable position, the invention being easily manipulated, able to support the orthodontic biomechanics, presenting a low elastic module, enabling transactions of heavy arcs reducing the risk of unwanted appliance detachments, also having a low viscosity, penetrating into the bracket retentions and in those retentions performed with the acid etching in the surface of the enamel. The adhesives actuate in both the base of the appliances and the enamel, the film thickness being minimal and does not alter the prescription of the system. When the appliance is removed at the end of the treatment, this will not damage the structure of the enamel, since the adhesive remains in the enamel, which is easily removed by a rotating device.
Abnormal interoceptive processing is observed across psychiatric and neurological conditions wherein core symptoms are motivated by diffuse bodily feeling: pervasive negative mood in Major Depression, compulsive urge in Obsessive Compulsive Disorder, urge to tic in Tourette Syndrome, and craving in addiction. Despite the prevalence of interoceptive abnormality, there is a scarcity of data on neurovisceral interactions in clinical populations. This knowledge gap can be attributed in part to a need for objective, neural measures of interoceptive processing. A candidate neural measure is the heartbeat evoked potential (HEP), a brain electrophysiological signal that is time-locked to the heartbeat and thought to index baroreceptor sensation in the chest cavity. While promising, basic characteristics of this signal are unknown, which limits its application to mechanistic and clinical research. Cortical sources of the HEP have been identified in the insula, yet spatial and temporal characteristics diverge across experimental paradigms. This suggests multiple functional correlates and cortical sources of the HEP index, including the insula. An added challenge is that the insula may be too deep for non-invasive recording and modulation, which necessitates invasive neural recording to explain non-invasive measures. Aim 1 validates neural source generators of the HEP with simultaneous invasive stereoelectroencephalography and dense array EEG on the scalp surface, while patients complete a battery of interoceptive tasks. Aim 2 investigates neural network dynamics during interoceptive attention, arousal and anticipation: theorizing that key clinical symptoms (e.g., tic, compulsions, negative mood) are learned behaviors in response to interoceptive cues, the research team tests the specific hypothesis that interoceptive activity is a predictor of reward-based decisions, particularly when decision-making demands a go with your gut strategy as reward outcomes are learned. Critically, Aim 3 then applies a deep breathing strategy to strategically perturb cardiac dynamics and disambiguate functional correlates of the HEP signal. Outcomes define properties of the HEP signal that must be known for this measurement strategy to inform and validate models of abnormal interoceptive circuit dynamics involving maladaptive responses to bodily distress.
The Real Stimulation of rTMS lasted 25 mins and delivered at 10 Hz with 1s duration,4s rest, a total of 3000 pulses at 100% of the rest motor threshold (RMT) . Behavior and MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
Gait enables individuals to move forward and is considered a natural skill. However, gait disturbances are very common in patients with burn injury. Major causes of functional impairment are pain and joint contractures. Contractures at the lower extremities such as the hip, knee, and ankle significantly limit gait. Recent studies focused on the application of robot-assisted gait training (RAGT).

This single-blinded, randomized, controlled trial involved 40 patients with lower extremity burns. Patients were randomized into a RAGT or a CON group.

SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern. Patients underwent 30 min of RAGT using SUBAR® and conventional exercise rehabilitation each for 30 min once a day for 5 days a week for 12 weeks. The CON group focused on gait training such as passive ROM exercise, weight bearing training, manual lymphatic drainage, and hypertrophic scar care for 60 min once a day for 5 days a week for 12 weeks.

A wearable functional near-infrared spectroscopy (fNIRS) device has been developed for studying cortical hemodynamics. Changes in cortical activity has not previously been documented in patients with burn injury. Cortical activity was measured by evaluating relative changes in oxyhemoglobin level. The NIRST Analysis Tool v2.1 was utilized to analyze fNIRS data in a MATLAB environment. Functional scores of functional ambulation category (FAC), 6-minute walking test (6MWT) distances, and numeric rating scale (NRS) scores of pain before and after 12 weeks RAGT were measured. Numeric rating scale (NRS) was used to rate the degree of subjective pain during gait movement: 0 points were assigned when no pain was noted, and unbearable pain was assigned 10 points. To evaluate functional recovery, FAC scores and 6-minute walking test (6MWT) distances were measured. FAC was evaluated based on six scales. Scale 0 means that the patient cannot walk or can only walk with assistance of two people. Scale 5 means that the patient can walk independently. We measured walking-related cortical activity using an fNIRS device before and after 12 weeks RAGT.
The invention provides a propolis oral spray. The propolis oral spray is a water solution containing 80-120g/L propolis, 120-160mL/L Tween 80 and 180-220mL/L ethanol. The invention also provides a method for preparing the propolis oral spray. The method comprises the following steps: (1) dissolving the propolis into ethanol, so as to prepare a first solution; (2) dissolving the Tween 80 into water, so as to prepare a second solution; and (3) heating the second solution to 70-90 DEG C, adding the first solution to the second solution, and evenly mixing, so as to obtain the propolis oral spray. On the other hand, the invention also provides the propolis oral spray, or use thereof in preparation of a pharmaceutical composition for preventing and/or treating a dental ulcer. By adopting the technical scheme, the propolis content in the healthcare propolis oral spray disclosed by the invention is increased to about 10wt%, and a better anti-inflammatory effect is obtained.
Patients will be treated with pembrolizumab 200 mg IV once every 3 weeks in combination with IL-2 given at 5 million IU subcutaneously twice daily for 3 weeks (5 days on, 2 days off each week, first dose in clinic and subsequent doses at home). IL-2 will be given only for the three weeks, after which pembrolizumab will be continued as monotherapy at either 200 mg every 3 weeks or 400 mg every 6 weeks.
The present invention relates to a method for determining the effect of a drug or a treatments, comprising introducing, in a non-human vertebrate recipient which may be an immunodeficient, e.g. a nude mouse, cells from a donor vertebrate, e.g. a human, which mediate the disease, the donor cell or cells of the recipient being modified, e.g. marked with a genetic marker such as lacZ gene, administering the drug or the treatment to the non-human recipient vertebrate, and determining the effect of the drug or the treatment. When the genetic marker is lacZ gene, the detection is performed by staining with the chromogenic substrate X-gal resulting in a blue staining of the labelled cell. In a further aspect, the invention relates to a method for controlling the progression of cancer cells in a human or animal patient, comprising administering to the patient fibroblasts which have been transformed with a genetic construct expressing a gene product inhibiting the progression of cancer cells.
INTRODUCTION: Schizophyllum commune (S. commune) is an opportunistic pathogenic fungus and can cause infection of the respiratory system in immunocompromised hosts. Allergic bronchopulmonary mycosis (ABPM) is the major disease caused by S. commune. However, identification of S. commune using routine mycological diagnostic methods is difficult. It is easy to make mistakes in diagnosis and treatment, resulting in deterioration of the disease. We report the first case of ABPM due to S. commune in a Chinese patient with chronic hepatitis B.
CASE PRESENTATION: The patient presented cough, sputum and dyspnea for six months. The pathogen was missed during routine laboratory workup. We performed bronchoscopy examination and bronchoalveolar lavage. S. commune was identified by metagenomic next-generation sequencing (mNGS) of bronchial alveolar lavage fluid (BALF). Hence, the patient was immediately treated with 200 mg voriconazole twice daily (intravenous infusion) and 20 mg prednisone once a day (oral therapy), along with oral entecavir for hepatitis B. There was no recurrence of infection after the medication was discontinued.
CONCLUSIONS: S. commune infection should be considered in the diagnosis of patients with refractory cough, sputum and dyspnea, especially in immunocompromised individuals. The mNGS technique is an effective supplementary technique for the diagnosis of S. commune infection, enabling precise clinical decision-making and appropriate treatment. Most patients have good prognosis with a combination of proper antifungal therapy and hormonal therapy.
Six 21-day cycles of docetaxel plus weekly placebo. Patients who have not experienced disease progression will continue to receive placebo weekly until progression.
OBJECTIVE: To evaluate the efficacy of treatment of hard-to-heal wounds of patients with ischaemia of the lower extremities, and compare an omega-3 wound matrix product (Kerecis, Iceland) with a standard dressing.
METHOD: A single-centre, prospective, randomised, controlled clinical trial of patients with hard-to-heal wounds following three weeks of standard care was undertaken. The ischaemic condition of the wound was confirmed as a decreased transcutaneous oxygen pressure (TcPO2) of <40mmHg. After randomising patients into either a case (omega-3 dressing) or a control group (standard dressing), the weekly decrease in wound area over 12 weeks and the number of patients that achieved complete wound closure were compared between the two groups. Patients with a TcPO2 of ≤32mmHg were taken for further analysis of their wound in a severe ischaemic context.
RESULTS: A total of 28 patients were assigned to the case group and 22 patients to the control group. Over the course of 12 weeks, the wound area decreased more rapidly in the case group than the control group. Complete wound healing occurred in 82% of patients in the case group and 45% in the control group. Even in patients with a severe ischaemic wound with a TcPO2 value of <32 mmHg, wound area decreased more rapidly in the case group than the control group. The proportions of re-epithelialised area in the case and control groups were 80.24% and 57.44%, respectively.
CONCLUSION: Considering the more rapid decrease in wound area and complete healing ratio in the case group, application of a fish skin-derived matrix for treating lower-extremity hard-to-heal wounds, especially with impaired vascularity, would appear to be a good treatment option.
Medical students with no previous experience in gynecological surgery will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
PURPOSE:To provide the titled water-based coating liquid, by adding a specific aromatic compound and a water-soluble gum to water or an aqueous solution of an alcohol as essential components, and dispersing a specific water-insoluble hydroxycarboxylic acid cellulose derivative powder in the solution. CONSTITUTION:An aromatic compound of formula I '(R1 and R2 are H, OCH3, etc.; R3 is CHO or CO2H) and a water-soluble gum (e.g. methylcellulose) are dissolved or dispersed in water or an aqueous solution of an alcohol containing <=20wt% 1-3C lower alcohol. The objective enteric coating liquid is produced by dispersing the powder of a water-insoluble hydroxycarboxylic acid cellulose derivative of formula II (Glu is glucose anhydride skeleton of cellulose and represented by C6H7O2; R1 is H or 1-5C carboxyalkyl; at least one of R2 and R3 is carboxy, etc. when R1 is H) and having particle diameter of <=100mu. The liquid is highly economically and safely.
Consenting volunteers between 40 and 70 years old with no morbidity, including males, and females who are not pregnant will be recruited for the study. Three volunteers will be enrolled with a reasonable sampling of ethnicities from the Nashville area, and an effort will be made to recruit males and females. The study will be conducted by the Vanderbilt Clinical Research Center (CRC).

Briefly, the three volunteers will be studied at a single dose level. Baseline assessments will be performed, and then each volunteer will be given a single oral dose (550 mg) of 2-HOBA. Ninety minutes after the dose, a lumbar puncture will be performed to obtain cerebrospinal fluid and a blood sample will be collected. 2-HOBA levels will be measured in cerebrospinal fluid and blood samples from this timepoint to assess the ability or orally ingested 2-HOBA to cross the blood brain barrier.
* Stop Tri-Nymyo if an arterial thrombotic event or venous thromboembolic (VTE) event occurs.
  * Stop Tri-Nymyo if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately[see Adverse Reactions (6.2)] .
  * If feasible, stop Tri-Nymyo at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE as well as during and following prolonged immobilization.
  * Start Tri-Nymyo no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.
  * The use of COCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 cases per 10,000 woman-years. The risk of VTE is highest during the first year of use of COCs and when restarting hormonal contraception after a break of 4 weeks or longer. The risk of thromboembolic disease due to COCs gradually disappears after use is discontinued.
  * Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes). This risk increases with age, particularly in women over 35 years of age who smoke.
  * Use COCs with caution in women with cardiovascular disease risk factors.
The widespread manufacture of silica and its extensive use, and potential release of silica into the environment pose a serious human health hazard. Silicosis, a severe global public health issue, is caused by exposure to silica, leading to persistent inflammation and fibrosis of the lungs. The underlying pathogenic mechanisms of silicosis remain elusive. Lung microbiota dysbiosis is associated with the development of inflammation and fibrosis. However, limited information is currently available regarding the role of lung microbiota in silicosis. The study therefore is designed to conduct a comprehensive analysis of the role of lung microbiota dysbiosis and establish a basis for future investigations into the potential mechanisms underlying silicosis. Here, the pathological and biochemical parameters were used to systematically assessed the degree of inflammation and fibrosis following silica exposure and treatment with combined antibiotics. The underlying mechanisms were studied via integrative multi-omics analyses of the transcriptome and microbiome. Analysis of 16S ribosomal DNA revealed dysbiosis of the microbial community in silicosis, characterized by a predominance of gram-negative bacteria. Exposure to silica has been shown to trigger lung inflammation and fibrosis, leading to an increased concentration of lipopolysaccharides in the bronchoalveolar lavage fluid. Furthermore, Toll-like receptor 4 was identified as a key molecule in the lung microbiota dysbiosis associated with silica-induced lung fibrosis. All of these outcomes can be partially controlled through combined antibiotic administration. The study findings demonstrate that the dysbiosis of lung microbiota enhances silica-induced fibrosis associated with the lipopolysaccharides/Toll-like receptor 4 pathway and provided a promising target for therapeutic intervention of silicosis.
Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily.
The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. In particular, the therapeutic/bioactive agents are covalently bound to the cyclodextrin-containing polymers. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distribution kits containing or relating to the polymeric compounds described herein.
PROBLEM TO BE SOLVED: To obtain the subject composition which retains dextranase stability and possesses high repressive effect for formation of dental calculus even when calcium phosphate and the like are formulated thereto as abrasives by using dextranase and pyrithiones or their salts in combination. SOLUTION: The objective composition is obtained by using dextranase and pyrithiones in combination. Dextranase is suitably formulated in an amount of 0.5-500 units, particularly 1.5-200 units, per 1g of the oral composition. The pyrithiones possess 2-mercaptopyridine N-oxide as the fundamental frame and include pyrithione derivatives and their tautomeric isomers having substituents in 3,4,5 and 6-positions of the pyritione frame. Their salts can be suitably selected from among pharmaceutically permissible ranges, e.g. monovalent or polyvalent metal salts and ammonium salts. These pyrithiones or their salts are preferably formulated in an amount of 0.01-5wt.% based on the whole weight of the composition.
This study is a parallel pragmatic cluster-randomized control trial evaluating the efficacy and cost-utility of a JCTH+-integrated services, as compared to service-as-usual among tertiary education institutions in Hong Kong. Randomisation will be carried out at institution level based on a computer-generated sequence. The estimated sample size will be 1,684, with 842 participants per condition. A factorial design will be adopted with all eligible participants completing assessments at 7 timepoints: baseline, 4 months post-test, 8-, 12-, 16-, 20- and 24-months follow-up. The primary endpoint is 4 months at post-test after baseline assessment. Concurrently, all staff involved in the project will be interviewed qualitatively at 12 months and 24 months from enrolment to understand their experience in the integration process and effectiveness of implementation.
The invention provides a duck circovirus strain and a preparation method of an inactivated vaccine thereof, belonging to the technical field of virus vaccine strains. The preservation number of the duck circovirus strain FJ1815 is CGMCC No. 16283. The duck circovirus inactivated vaccine prepared based on the duck circovirus strain FJ1815 is the first vaccine for preventing and controlling duck circovirus disease at home and abroad, and after 21 days of using the inactivated vaccine to immunize ducks, ducks can be induced to generate high-level specific antibodies aiming at the duck circovirus, so that the duck circovirus infection can be effectively resisted. The inactivated vaccine has good immunogenicity, and the immune protection rate is as high as 100%. The popularization and application of the vaccine are beneficial to preventing and controlling the infection and the prevalence of the duck circovirus in duck groups, and the vaccine has wide application prospect.